Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

Published:2019-06-07 Issue:6 Volume:2 Page:e194765
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

McGlynn Elizabeth A.¹,Adams John L.²,Kramer Jason²,Sahota Amandeep K.³,Silverberg Michael J.⁴,Shenkman Elizabeth⁵,Nelson David R.⁶

Affiliation:

1. Kaiser Permanente Research, Kaiser Permanente, Pasadena, California

2. Kaiser Permanente Center for Effectiveness and Safety Research, Kaiser Permanente, Pasadena, California

3. Department of Internal Medicine, Transplant Hepatology, Southern California Permanente Medical Group, Los Angeles

4. Division of Research, Kaiser Permanente Northern California, Oakland

5. Department of Health Outcomes & Biomedical Informatics, University of Florida College of Medicine, Gainesville

6. Department of Medicine, University of Florida College of Medicine, Gainesville

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/6/e194765/17635216/mcglynn_2019_oi_190200.pdf

Reference35 articles.

1. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.;Hofmeister;Hepatology,2019

2. Changing trends in complications of chronic hepatitis C.;Lu;Liver Int,2018

3. The natural history of hepatitis C virus (HCV) infection.;Chen;Int J Med Sci,2006

4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.;Fried;N Engl J Med,2002

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.;Manns;Lancet,2001

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells;Biomedicine & Pharmacotherapy;2024-10

2. United States Provider Experiences with Telemedicine for Hepatitis C Treatment: A Nationwide Survey;2024-05-13

3. Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report;Current Drug Safety;2024-02

4. Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis;IJC Heart & Vasculature;2023-12

5. Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder;Health Expectations;2023-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3